ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26Total du passif1.01 M1.27 M1.21 M1.67 M1.34 M950 KTotal des capitaux propres4.72 M12.17 M10.1 M9.84 M20.15 M16.46 MTotal du passif et des capitaux propres5.74 M13.44 M11.3 M11.51 M21.49 M17.41 MDette totale——————Dette nette——————
Phio Pharmaceuticals Corp. - Common Stock
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.